Drugs / Preg-Mom
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07399717 | Jan → Dec 2026 expected | pneumonia | Anabio R&D | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Preg-Mom | “LiveSpo® Preg-Mom oral probiotic suspension” NCT07399717 ↗ |
| Known as | LiveSpo PREG-MOM | “LiveSpo® Preg-Mom oral probiotic suspension” NCT07399717 ↗ |
| Modality | Other / unclassified | “oral probiotics (LiveSpo Pregmom containing Bacillus subtilis, Bacillus clausii, and Bacillus coagulans, 3x10\^9 CFU/5 mL)” NCT07399717 ↗ |
| Route | Oral | “The Navax-PregMom group is also given oral medication with LiveSpo® Preg-Mom” NCT07399717 ↗ |